Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 3/20 | 0.59 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.44 |
| ▸ | HTR2C | P28335 | 1/20 | 0.44 |
| ▸ | PHGDH | O43175 | 1/20 | 0.44 |
| ▸ | PKM | P14618 | 3/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.43 |
| ▸ | PLAUR | Q03405 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 2/20 | 0.43 |
| ▸ | RAB9A | P51151 | 2/20 | 0.43 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11100629 | 0.86 | GAA (0.51) | HPGDALDH1A1PKMMAPTHSP90AA1 | |
| SCHEMBL14887797 | 0.84 | ALDH1A1 (0.53) | HPGDALDH1A1PKMMAPTHSP90AA1 | |
| SCHEMBL27490431 | 0.81 | ALDH1A1 (0.43) | HPGDALDH1A1PKMMAPTHSP90AA1 | |
| SCHEMBL30194846 | 0.80 | PIK3CD (0.50) | L3MBTL1ALDH1A1HTR2CPKMMAPT | |
| Ethylene SCHEMBL8377729 | 0.79 | ALDH1A1 (0.41) | HPGDALDH1A1PKMMAPTHSP90AA1 | |
| SCHEMBL15921792 | 0.77 | HPGD (0.60) | HPGDL3MBTL1SMN1; SMN2ALDH1A1HTR2C | |
| SCHEMBL28478515 | 0.76 | ALDH1A1 (0.45) | L3MBTL1ALDH1A1PKMMAPTHSP90AA1 | |
| SCHEMBL19029825 | 0.76 | PIK3CD (0.40) | ALDH1A1PKMMAPTHSP90AA1PIK3CD | |
| SCHEMBL20301969 | 0.75 | HPGD (0.57) | HPGDL3MBTL1SMN1; SMN2ALDH1A1HTR2C | |
| SCHEMBL31738591 | 0.75 | PIK3CD (0.48) | SMN1; SMN2ALDH1A1PKMMAPTHSP90AA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250091994-A1 | RAS/RAF BINDING INHIBITOR COMPOUND | NATIONAL UNIVERSITY CORPORATION KOBE UNIVERSITY (JP) | 2025-03-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250091994-A1 | RAS/RAF BINDING INHIBITOR COMPOUND | BRAF, RAF1, NRAS | HPGD 4233/4885L3MBTL1 1560/4885SMN1; SMN2 4832/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.